IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.1% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 11,328 shares of the company’s stock after selling 1,555 shares during the period. State of Alaska Department of Revenue’s holdings in IDEXX Laboratories were worth $5,722,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in IDEXX Laboratories by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company’s stock valued at $4,576,476,000 after purchasing an additional 98,387 shares in the last quarter. American Century Companies Inc. increased its position in shares of IDEXX Laboratories by 46.0% in the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock valued at $274,179,000 after acquiring an additional 177,226 shares during the period. International Assets Investment Management LLC raised its stake in IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after acquiring an additional 527,460 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in IDEXX Laboratories by 13.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company’s stock worth $249,855,000 after acquiring an additional 59,519 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in IDEXX Laboratories by 12.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 390,565 shares of the company’s stock valued at $190,283,000 after purchasing an additional 43,473 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.4 %

IDXX stock opened at $449.44 on Tuesday. The firm’s fifty day moving average is $483.67 and its 200 day moving average is $488.84. The firm has a market cap of $37.12 billion, a PE ratio of 43.51, a P/E/G ratio of 4.03 and a beta of 1.33. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing the consensus estimate of $2.88 by ($0.44). The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.01 billion. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. IDEXX Laboratories’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.67 EPS. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Piper Sandler decreased their price objective on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a research note on Wednesday, August 14th. JPMorgan Chase & Co. cut their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Finally, BTIG Research assumed coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target on the stock. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $574.13.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.